Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 1Papilloma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1

Interventions

ponatinib 4pembrolizumab 3Rituximab 3Gemcitabine 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3pralsetinib 2napabucasin 2Vincristine 2Prednisone 2Irinotecan 2Imatinib Mesylate 2Etoposide 2Doxorubicin 2Carboplatin 2Brentuximab Vedotin 2tetulomab tetraxetan lu-177 1ruxolitinib 1ricolinostat 1pomalidomide 1pamiparib 1nirogacestat 1nilotinib 1ibritumomab tiuxetan 1denileukin diftitox 1bosutinib 1blinatumomab 1Vorinostat 1Temozolomide 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms by Histologic Type × Human Papillomavirus DNA Tests × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡